MORRIS PLAINS, N.J., Nov. 11, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 7 presentations involving 6 of its product candidates have been accepted for presentation at the 52nd American Society of Hematology (ASH) Annual Meeting, scheduled for December 4 - 7, 2010, in Orlando, FL. The abstracts include oral and poster presentations across a spectrum of hematologic malignancies and autoimmune diseases. The schedule and meeting places for the presentations, together with the publication and board numbers, are listed below:
